Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women (FM-01)
Overweight and Obesity, Dyslipoproteinemia
About this trial
This is an interventional treatment trial for Overweight and Obesity focused on measuring Weight Management Programs, Weight loss stabilization, Cardiometabolic risk
Eligibility Criteria
Inclusion Criteria:
- BMI: between 27.0 and 34.9 kg/m²
- One of the following blood lipids: total cholesterol ≥ 200 mg/dL, LDL-cholesterol ≥ 175 mg/dL, HDL-cholesterol ≤ 50 mg/dL, TG 150-400 mg/dL
- women, 18-60 years
Specific Exclusion Criteria:
- lactose or protein intolerance
- hypo- or hyperthyroidism
- pharmacological treatment of diabetes
- intake of vitamins or mineral supplements
- anticoagulants
- cardiac pacemaker
- contraindications to exercise
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Other
Active Comparator
Placebo Comparator
Meal replacement (MR) group
Control (C) group
Verum group
Placebo group
Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1) During weight stabilization phase (phase 2) MR counted to food choice option.
Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1) During 3-month weight stabilization phase (phase 2) MR counted to food choice option.
Specific micronutrient composition with omega-3 fatty acids (capsules) Duration: 6-month weight maintenance phase (phase 3)
Placebo capsules Duration: 6-month weight maintenance phase (phase 3)